Becton, Dickinson and Company (BDX) Stock Analysis
Healthcare · Medical Instruments & Supplies · NYSE
Becton, Dickinson and Company (BDX) posted $21.84B in revenue for fiscal 2025 (up 8.2% year over year), at a 7.7% net margin, and has compounded revenue about 6.3%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Becton, Dickinson and Company
Becton, Dickinson and Company has grown revenue from $12.48B to $21.84B over the last 10 fiscal years, compounding about 6.3% a year. The most recent year was up 8.2%, so growth is actually accelerating.
Net margin sits at 7.7%, down 0.7 points year over year on a 45.4% gross margin. It carries about $19.18B of total debt.
The one thing worth a second look in the filings is heavy debt load.
Synthesised from Becton, Dickinson and Company's SEC filings — descriptive, not advice. Ask the analyst your own question →
Becton, Dickinson and Company revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.48B | $12.09B | $15.98B | $17.29B | $16.07B | $19.13B | $18.87B | $19.37B | $20.18B | $21.84B |
| Gross profit | $5.99B | $5.94B | $7.27B | $8.29B | $7.58B | $8.63B | $8.48B | $8.17B | $9.13B | $9.93B |
| Net income | $976.00M | $1.10B | $311.00M | $1.23B | $874.00M | $2.09B | $1.78B | $1.48B | $1.71B | $1.68B |
| Net margin | 7.8% | 9.1% | 1.9% | 7.1% | 5.4% | 10.9% | 9.4% | 7.7% | 8.4% | 7.7% |
Source: Becton, Dickinson and Company SEC filings (10-K). 19 years of history available in the interactive view.
Becton, Dickinson and Company: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Heavy debt loadTotal debt of $19179M is 5.6× last year's operating cash flow — it would take years of cash flow to clear.
Explore 19 years of Becton, Dickinson and Company financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BDX in your portfolio →
Becton, Dickinson and Company financial history by metric
Compare Becton, Dickinson and Company with peers
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Becton, Dickinson and Company — frequently asked questions
What is Becton, Dickinson and Company's revenue?
Becton, Dickinson and Company (BDX) reported revenue of $21.84B for fiscal year 2025, up 8.2% from the prior year, according to its SEC filings.
Is Becton, Dickinson and Company profitable?
Yes. BDX earned net income of $1.68B in fiscal 2025, a net margin of 7.7%.
What is BDX's P/E ratio?
Becton, Dickinson and Company trades at a price-to-earnings ratio of about 28.9 based on the latest data in our nightly-refreshed cache.
How fast is Becton, Dickinson and Company growing?
BDX's revenue grew at roughly 6.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Becton, Dickinson and Company have?
As of fiscal year 2025, BDX carried roughly $19.18B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Becton, Dickinson and Company's gross margin?
BDX's gross margin was 45.4% in fiscal 2025 — gross profit of $9.93B on revenue of $21.84B.
What is Becton, Dickinson and Company's market cap?
Becton, Dickinson and Company (BDX) has a market capitalization of about $0, based on the latest data in our nightly-refreshed cache.
When does Becton, Dickinson and Company's fiscal year end?
BDX's fiscal year ends in September. Its most recent annual filing covers the fiscal year ending 2025-09-30.
Where does this data come from?
All figures are computed from Becton, Dickinson and Company's official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.